Marengo Therapeutics, Inc., a US-based company involved in novel therapeutics targeting the T cell receptor (TCR) V-beta to selectively activate the right T cell subsets to fight cancer, announced on Friday that it has dosed its first subject in its ongoing clinical trial of STAR0602 (START-001).

The company's START-001 trial, a seamless Phase one/two clinical trial, is to assess the safety and clinical activity of STAR0602 as monotherapy in a biomarker-enriched cohort of patients with PD-1 refractory advanced solid tumours.

Presently, the trial is enrolling subjects at two top US cancer research institutes, National Institutes of Health (NIH)'s National Cancer Institute (NCI) and Mass General Hospital (MGH)/Harvard Medical School, co-led by seasoned clinical and translational researchers James Gulley, MD, PhD, of NCI and Ryan Sullivan, MD, of MGH. The company is planning to add more top cancer centres to support the further expansion of the study.